Advertisement

New Approaches for the Secondary Prevention of Cryptogenic Stroke Using Non-vitamin K Antagonist Oral Anticoagulants

  • Tomohisa Nezu
  • Yoshiki Yagita
Chapter

Abstract

Non-vitamin K antagonist oral anticoagulants (NOACs) were introduced to prevent systemic embolism in patients with non-valvular atrial fibrillation (AF), and the use of NOACs for secondary prevention of cardioembolic stroke in patients with AF has gradually increased. Recently, NOACs were also approved for the prevention for deep venous thrombosis. Therefore, ischemic stroke patients with paradoxical emboli who have right-to-left shunt (such as patent foramen ovale or pulmonary arteriovenous fistula) and deep venous thrombosis may be treated with NOACs. In addition, a new clinical concept, termed “Embolic Stroke of Undetermined Source” (ESUS), has recently been suggested. ESUS has been proposed as an indication for anticoagulation, because paroxysmal AF is a potential mechanism of stroke in ESUS patients. Some large randomized clinical trials have been initiated to determine whether NOACs are superior to antiplatelets for the prevention of recurrent stroke in patients with ESUS. In this review, we discuss the potential use of NOACs for secondary stroke prevention among ischemic stroke patients without AF, especially in patients with cryptogenic stroke.

Keywords

Cryptogenic stroke ESUS NOACs Anticoagulants 

References

  1. 1.
    Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91.CrossRefPubMedGoogle Scholar
  2. 2.
    Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.CrossRefPubMedGoogle Scholar
  3. 3.
    Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.CrossRefPubMedGoogle Scholar
  4. 4.
    Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104.CrossRefPubMedGoogle Scholar
  5. 5.
    Toyoda K, Arihiro S, Todo K, Yamagami H, Kimura K, Furui E, et al. Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in Japan: the SAMURAI-NVAF study. Int J Stroke. 2015;10(6):836–42.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(1):227–76.CrossRefPubMedGoogle Scholar
  7. 7.
    Marnane M, Duggan CA, Sheehan OC, Merwick A, Hannon N, Curtin D, et al. Stroke subtype classification to mechanism-specific and undetermined categories by TOAST, A-S-C-O, and causative classification system: direct comparison in the North Dublin population stroke study. Stroke. 2010;41(8):1579–86.CrossRefPubMedGoogle Scholar
  8. 8.
    Grau AJ, Weimar C, Buggle F, Heinrich A, Goertler M, Neumaier S, et al. Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke. 2001;32(11):2559–66.CrossRefPubMedGoogle Scholar
  9. 9.
    Bang OY, Lee PH, Joo SY, Lee JS, Joo IS, Huh K. Frequency and mechanisms of stroke recurrence after cryptogenic stroke. Ann Neurol. 2003;54(2):227–34.CrossRefPubMedGoogle Scholar
  10. 10.
    Bal S, Patel SK, Almekhlafi M, Modi J, Demchuk AM, Coutts SB. High rate of magnetic resonance imaging stroke recurrence in cryptogenic transient ischemic attack and minor stroke patients. Stroke. 2012;43(12):3387–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Hart RG, Diener HC, Coutts SB, Easton JD, Granger CB, O'Donnell MJ, et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 2014;13(4):429–38.CrossRefPubMedGoogle Scholar
  12. 12.
    Liao J, Khalid Z, Scallan C, Morillo C, O'Donnell M. Noninvasive cardiac monitoring for detecting paroxysmal atrial fibrillation or flutter after acute ischemic stroke: a systematic review. Stroke. 2007;38(11):2935–40.CrossRefPubMedGoogle Scholar
  13. 13.
    Kishore A, Vail A, Majid A, Dawson J, Lees KR, Tyrrell PJ, et al. Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Stroke. 2014;45(2):520–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014;370(26):2478–86.CrossRefPubMedGoogle Scholar
  15. 15.
    Gladstone DJ, Spring M, Dorian P, Panzov V, Thorpe KE, Hall J, et al. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med. 2014;370(26):2467–77.CrossRefPubMedGoogle Scholar
  16. 16.
    Thijs VN, Brachmann J, Morillo CA, Passman RS, Sanna T, Bernstein RA, et al. Predictors for atrial fibrillation detection after cryptogenic stroke: results from CRYSTAL AF. Neurology. 2016;86(3):261–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Hoshino T, Nagao T, Shiga T, Maruyama K, Toi S, Mizuno S, et al. Prolonged QTc interval predicts poststroke paroxysmal atrial fibrillation. Stroke. 2015;46(1):71–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Gladstone DJ, Dorian P, Spring M, Panzov V, Mamdani M, Healey JS, et al. Atrial premature beats predict atrial fibrillation in cryptogenic stroke: results from the EMBRACE trial. Stroke. 2015;46(4):936–41.CrossRefPubMedGoogle Scholar
  19. 19.
    Kochhäuser S, Dechering DG, Dittrich R, Reinke F, Ritter MA, Ramtin S, et al. Supraventricular premature beats and short atrial runs predict atrial fibrillation in continuously monitored patients with cryptogenic stroke. Stroke. 2014;45(3):884–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Stahrenberg R, Edelmann F, Haase B, Lahno R, Seegers J, Weber-Krüger M, et al. Transthoracic echocardiography to rule out paroxysmal atrial fibrillation as a cause of stroke or transient ischemic attack. Stroke. 2011;42(12):3643–5.CrossRefPubMedGoogle Scholar
  21. 21.
    Shibazaki K, Kimura K, Fujii S, Sakai K, Iguchi Y. Brain natriuretic peptide levels as a predictor for new atrial fibrillation during hospitalization in patients with acute ischemic stroke. Am J Cardiol. 2012;109(9):1303–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Loscalzo J. Paradoxical embolism: clinical presentation, diagnostic strategies, and therapeutic options. Am Heart J. 1986;112(1):141–5.CrossRefPubMedGoogle Scholar
  23. 23.
    Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP. Investigators PiCSSP. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in cryptogenic stroke study. Circulation. 2002;105(22):2625–31.CrossRefPubMedGoogle Scholar
  24. 24.
    Handke M, Harloff A, Olschewski M, Hetzel A, Geibel A. Patent foramen ovale and cryptogenic stroke in older patients. N Engl J Med. 2007;357(22):2262–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Homma S, Sacco RL. Patent foramen ovale and stroke. Circulation. 2005;112(7):1063–72.CrossRefPubMedGoogle Scholar
  26. 26.
    Schuchlenz HW, Weihs W, Horner S, Quehenberger F. The association between the diameter of a patent foramen ovale and the risk of embolic cerebrovascular events. Am J Med. 2000;109(6):456–62.CrossRefPubMedGoogle Scholar
  27. 27.
    Mas JL, Arquizan C, Lamy C, Zuber M, Cabanes L, Derumeaux G, et al. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med. 2001;345(24):1740–6.CrossRefPubMedGoogle Scholar
  28. 28.
    Serena J, Marti-Fàbregas J, Santamarina E, Rodríguez JJ, Perez-Ayuso MJ, Masjuan J, et al. Recurrent stroke and massive right-to-left shunt: results from the prospective Spanish multicenter (CODICIA) study. Stroke. 2008;39(12):3131–6.CrossRefPubMedGoogle Scholar
  29. 29.
    Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(7):2160–236.CrossRefPubMedGoogle Scholar
  30. 30.
    Wells PS, Forgie MA, Rodger MA. Treatment of venous thromboembolism. JAMA. 2014;311(7):717–28.CrossRefPubMedGoogle Scholar
  31. 31.
    Di Tullio MR, Russo C, Jin Z, Sacco RL, Mohr JP, Homma S, et al. Aortic arch plaques and risk of recurrent stroke and death. Circulation. 2009;119(17):2376–82.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Amarenco P, Cohen A, Tzourio C, Bertrand B, Hommel M, Besson G, et al. Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N Engl J Med. 1994;331(22):1474–9.CrossRefPubMedGoogle Scholar
  33. 33.
    The French Study of Aortic Plaques in Stroke Group. Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke. N Engl J Med. 1996;334(19):1216–21.Google Scholar
  34. 34.
    Di Tullio MR, Sacco RL, Gersony D, Nayak H, Weslow RG, Kargman DE, et al. Aortic atheromas and acute ischemic stroke: a transesophageal echocardiographic study in an ethnically mixed population. Neurology. 1996;46(6):1560–6.CrossRefPubMedGoogle Scholar
  35. 35.
    Chhabra L, Niroula R, Phadke J, Spodick DH. Retrograde embolism from the descending thoracic aorta causing stroke: an underappreciated clinical condition. Indian Heart J. 2013;65(3):319–22.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Harloff A, Simon J, Brendecke S, Assefa D, Helbing T, Frydrychowicz A, et al. Complex plaques in the proximal descending aorta: an underestimated embolic source of stroke. Stroke. 2010;41(6):1145–50.CrossRefPubMedGoogle Scholar
  37. 37.
    Katsanos AH, Giannopoulos S, Kosmidou M, Voumvourakis K, Parissis JT, Kyritsis AP, et al. Complex atheromatous plaques in the descending aorta and the risk of stroke: a systematic review and meta-analysis. Stroke. 2014;45(6):1764–70.CrossRefPubMedGoogle Scholar
  38. 38.
    Amarenco P, Davis S, Jones EF, Cohen AA, Heiss WD, Kaste M, et al. Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques. Stroke. 2014;45(5):1248–57.CrossRefPubMedGoogle Scholar
  39. 39.
    Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001;345(20):1444–51.CrossRefPubMedGoogle Scholar
  40. 40.
    Diener HC, Easton JD, Granger CB, Cronin L, Duffy C, Cotton D, et al. Design of Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS). Int J Stroke. 2015;10(8):1309–12.PubMedGoogle Scholar
  41. 41.
    Markus HS, Hayter E, Levi C, Feldman A, Venables G, Norris J, et al. Antiplatelet treatment compared with anticoagulation treatment for cervical artery dissection (CADISS): a randomised trial. Lancet Neurol. 2015;14(4):361–7.CrossRefPubMedGoogle Scholar
  42. 42.
    Caprio FZ, Bernstein RA, Alberts MJ, Curran Y, Bergman D, Korutz AW, et al. Efficacy and safety of novel oral anticoagulants in patients with cervical artery dissections. Cerebrovasc Dis. 2014;38(4):247–53.CrossRefPubMedGoogle Scholar
  43. 43.
    Keeling D, Mackie I, Moore GW, Greer IA, Greaves M. Haematology BCfSi. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol. 2012;157(1):47–58.CrossRefPubMedGoogle Scholar
  44. 44.
    Cohen H, Doré CJ, Clawson S, Hunt BJ, Isenberg D, Khamashta M, et al. Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE. Lupus. 2015;24(10):1087–94.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Yaghi S, Kamel H, Elkind MS. Potential new uses of non-vitamin K antagonist oral anticoagulants to treat and prevent stroke. Neurology. 2015;85(12):1078–84.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media Singapore 2017

Authors and Affiliations

  1. 1.Department of Clinical Neuroscience and TherapeuticsHiroshima University, Graduate School of Biomedical & Health SciencesHiroshimaJapan
  2. 2.Department of Stroke MedicineKawasaki Medical SchoolKurashikiJapan

Personalised recommendations